Congenital myasthenic syndromes are inherited disorders of neuromuscular transmission characterized by fatigable muscle weakness. Autosomal recessive acetylcholine receptor (AChR) deficiency syndromes, in which levels of this receptor at the neuromuscular junction are severely reduced, may be caused by mutations within genes encoding the AChR or the AChR-clustering protein, rapsyn. Most patients have mutations within the rapsyn coding region and are either homozygous for N88K or heteroallelic for N88K and a second mutation. In some cases the second allele carries a null mutation but in many the mutations are missense, and are located in different functional domains. Little is known about the functional effects of these mutations, but we hypothesize that they would have an effect on AChR clustering by a variety of mechanisms that might correlate with disease severity. Here we expressed RAPSN mutations A25V, N88K, R91L, L361R and K373del in TE671 cells and in rapsyn-/-myotubes to determine their pathogenic mechanisms. The A25Vmutation impaired colocalization of rapsyn with AChR and prevented agrin-induced AChR clusters in rapsyn-/-myotubes. In TE671 cells, R91L reduced the ability of rapsyn to self-associate, and K373del-rapsyn was significantly less stable than wild-type. The effects of mutations L361R and N88K were more subtle: in TE671 cells, in comparison with wild-type rapsyn, L361R-rapsyn showed reduced expression/stability, and both N88K-rapsyn and L361R-rapsyn showed significantly reduced co-localization with AChR. N88K-rapsyn and L361R-rapsyn could effectively mediate agrin-induced AChR clusters, but these were reduced in number and were less stable than with wild-type rapsyn. The disease severity of patients harbouring the compound allelic mutations was greater than that of patients with homozygous rapsyn mutation N88K, suggesting that the second mutant allele may largely determine severity. and are either homozygous for N88K or heteroallelic for N88K and a second mutation. In some cases the second allele carries a null mutation but in many the mutations are missense, and are located in different functional domains. Little is known about the functional effects of these mutations, but we hypothesise that they would have an effect on AChR clustering by a variety of mechanisms that might correlate with disease severity.
Introduction
Synaptic transmission plays a pivotal role in controlling the passage of information through the nervous system. Synaptogenesis involves the juxtaposition of pre-and postsynaptic structures and the generation of regions of densely packed neurotransmitter receptors. At the neuromuscular junction (NMJ) a core pathway involving agrin, muscle-specific tyrosine kinase (MuSK), acetylcholine receptors (AChRs) and the AChR-clustering protein rapsyn is thought to be responsible for maintaining synaptic structure and for the aggregation and localisation of AChR on the postsynaptic folds (Sanes and Lichtman, 2001) . Although mutations underlying congenital myasthenic syndromes (Engel and Sine, 2005) have been identified in postsynaptically-expressed genes encoding MuSK (Chevessier et al., 2004) and the voltage gated sodium channel, Na v 1.4 (Tsujino et al., 2003) , the majority are located in the AChR or rapsyn genes (a list of these mutations is given in Ohno and Engel, 2004) . AChR mutations have been well studied, but the functional effects of rapsyn genes have not yet been characterised in detail.
In early developmental stages the AChR is expressed throughout muscle, with clusters or 'hot-spots' of AChR forming independently of the nerve in the process of muscle prepatterning (Kummer et al., 2005) .
Motoneuron axons then extend into the muscle and release agrin, which activates MuSK through an as yet undetermined mechanism. AChRs are phosphorylated and their expression becomes restricted to the synaptic and perisynaptic regions of the muscle. As the junction matures, dense, stable clusters of AChR become localised at the crests of the post-synaptic folds of the NMJ. Rapsyn interacts directly with AChRs and is essential for agrin-induced clustering of the AChR (Fuhrer et al., 1999; Gautam et al., 1995) . In rapsyn -/-mice AChR clusters fail to form, the postsynaptic folds do not form properly, nerve sprouting occurs and the mice die at birth without functional synapses Gautam et al., 1995) . AChRs, in turn, are required for synaptic clustering of rapsyn, revealing an intimate functional interdependence of AChRs and rapsyn (Marangi et al., 2001; Ono et al., 2004) .
The effect of deletions and truncations of rapsyn on its function in vitro have led to the proposal of four functional domains: rapsyn is attached to the juxtaneural postsynaptic membrane by a myristylation moiety; seven tetratricopeptide repeat (TPR) domains are thought to mediate rapsyn self-association (Eckler et al., 2005; Ramarao et al., 2001 ); a zinc finger/coiled-coil domain has been implicated in interaction of rapsyn with the AChR (Bezakova and Bloch, 1998; Ramarao et al., 2001) ; and a RING-H2 domain is thought to be involved in rapsyn binding to scaffolding proteins such as dystroglycan (Bartoli et al., 2001 ).
Mutations within the RAPSN gene have been shown to underlie a high proportion of AChR deficiency syndromes (Burke et al., 2003; Dunne and Maselli, 2003; Ioos et al., 2004; Maselli et al., 2003; Muller et al., 2003; Ohno et al., 2002; Ohno et al., 2003) which can occur early in life or during adulthood.
The disease is recessive, and in most cases patients are either homozygous for N88K or heteroallelic for N88K and a second mutation. The severity of disease is variable, ranging from little functional impairment to the patient requiring assisted ventilation. In particular, the disorder in childhood is frequently characterised by severe apnoeic attacks. To date the precise mechanisms by which these different RAPSN mutations lead to AChR deficiency have not been thoroughly studied.
Here we investigated the functional effects of five RAPSN gene mutations, including N88K, and asked whether these correlated with the clinical phenotype. Our data show that diverse molecular mechanisms disrupt rapsyn function, and that the major effect of N88K-rapsyn is to reduce the stability of AChR-clusters. However, in compound heterozygotes of N88K and a second mutation, the second mutant allele is likely to play a role in determining disease severity.
Materials and Methods

Patients with AChR deficiency and the identification of RAPSN mutations
Patients and DNA samples were recruited through the congenital myasthenia service in Oxford, UK.
All were negative for antibodies against the AChR. Information was from family interviews, case note review and clinical examination obtained by an assessor blinded to the results of the genetic functional analysis. Assessment was complimented by the myasthenia activities of daily living scoring system (MG-ADL); an eight-question survey of symptom severity, with each response graded from 0 (normal) to 3 (most severe) (Wolfe et al., 1999) . Mutations were identified by direct sequencing of PCR amplicons containing the eight RAPSN exons and their flanking non-coding regions and confirmed by restriction endonuclease digestion as described previously (Burke et al., 2004) . Approval for this study was obtained from the Central
Oxford Research Ethics Committee
Plasmids and constructs
pBabe-PURO-sn was a kind gift from Dr Chris Norbury, Cancer Research UK, WIMM, Oxford.
pEGFP-N1 was purchased from Clontech. Restriction enzymes were purchased from New England Biolabs.
Human rapsyn cDNA minus the stop codon was amplified using primers 5'-TGCGAAGCTTGCCACCATGGGGCAGGACCAGACCAAG and 5'-TCGTGGATCCCGTACAAAGCCAGGCTTCATGGA and was cloned into pEGFP-N1 using HindIII and BamHI restriction sites, such that EGFP and rapsyn were in the same reading frame. Mutagenesis was carried out using the QuikChange mutagenesis kit purchased from Stratagene. The primers that were used for mutagenesis were 5'-CCAGTCCAACCAGACAGAGAAGGTATTGCAGGTGTGGACAAAGG and by DNA sequencing. EGFP-tagged rapsyn and mutants were excised from pEGFP-N1 using HindIII (filled) and NotI, and were cloned into XhoI (filled) and NotI digested pBabe-PURO-sn.
Cell lines
TE671, COS-7 and C2C12 cells were purchased from ATCC and GP + E86 (Markowitz et al., 1988) retroviral-producing cell line was a kind gift from Professor Roy Bicknell, Cancer Research UK, WIMM Oxford. TE671, COS-7 and GP + E86 cell lines were maintained at 37°C in DMEM (Sigma-Aldrich) supplemented with 10% FCS (TCS Cellworks Ltd) and 100 units/ml each of penicillin G and streptomycin (PS) purchased from Invitrogen. C2C12 cells were maintained at 37°C in DMEM supplemented with 20% FCS and PS, and were fused in DMEM containing 2% FCS and PS. Rapsyn -/-(clone 11-7) myoblasts (Fuhrer et al., 1999) were maintained at 33°C with 5%CO 2 on plates coated with matrigel matrix (BD Biosciences Discovery Labware, San Hose, CA, USA). Growth media was DMEM supplemented with 0.5% chick embryo extract (United States Biological, MA, USA), 4 units/ml mouse recombinant interferon-γ (Sigma-Aldrich), 20% FCS and PS. To induce fusion, myoblasts were moved to 37°C with 5% CO 2 , and the media was replaced with fusion media (DMEM containing 10% horse serum (Sigma-Aldrich) and PS).
Fusion media was replaced every day until myotubes formed.
Transfections
TE671 cells were seeded at 2 x 10 5 cells per well in 6 well-plates and the following day were transfected with a total of 3μg DNA per well using calcium phosphate precipitation. Amounts of DNA used per well was 1μg
AChR α-subunit DNA, 0.5 μg each of AChR β-, δ-and ε-subunit cDNA and 0.5μg of rapsyn cDNAs or pcDNA3.1-hygro for 'no rapsyn' control transfections. Transfections with only rapsyn and no AChR were carried out using 3 μg/well of rapsyn expression plasmids. GP + E86 cells were transfected with the pBabe-PURO-rapsyn constructs using Fugene (Roche Diagnostics), using 2.5μg DNA and 7.5μl Fugene in a 25cm 2 flask. Three days following transfection cells were selected using 8μg/ml puromycin (Sigma-Aldrich), and two weeks later were cell-sorted to obtain the top 5% fluorescent cells.
Retroviral production and infection
For retroviral production transfected GP + E86 cells were incubated for three days in the minimal volume of growth media without puromycin. The media was harvested and centrifuged to remove cell debris, aliquoted and snap frozen on dry ice. Retrovirus was stored at -80°C. Retrovirus was used neat and was incubated with myoblasts overnight at 33°C after which the media was replaced with growth media.
Puromycin was added three days after infection. AChR on myotubes were labelled at 37°C with tetramethylrhodamine α-bungarotoxin (Molecular Probes) diluted 1:1000 in fusion media. Cells were washed 3 x in fusion media, fixed in fusion media containing 3%
formaldehyde for 20mins at room temp., washed 1x in PBS and mounted in fluorescent mounting media.
Images were captured by using Openlab software (Improvision) or LaserSharp 2000 software (BioRad).
Western blots
TE671 cells were removed from 6-well plates using trypsin/EDTA in PBS, centrifuged and the pellets were resuspended in 5x protein loading buffer. The cell extract was incubated at 95°C for 1 hour and then subjected to SDS PAGE using Novex precast 4-20% NuPage gels. Protein was transferred to nitrocellulose and rapsyn was detected using anti-rapsyn MAb 1234 (Abcam) followed by anti-mouse-HRP and ECL (Amersham). α-tubulin was detected on the same Western blots using a MAb (Sigma-Aldrich)
followed by anti-mouse-HRP and ECL.
Production of agrin and generation of AChR clusters on myotubes
To generate soluble rat agrin, COS cells were transiently transfected with construct s-agrin-(4,19), kindly given by Werner Hoch (Hopf and Hoch, 1997) , using PEI. On the following day the media was replaced with fresh media. Conditioned media was harvested two days later, aliquoted and snap frozen.
AChR clustering activity of the agrin was titrated by incubation overnight with C2C12 myotubes. Clusters were labelled at 37°C for 1 hour with tetramethylrhodamine α-bungarotoxin (Molecular Probes) diluted 1:1000 in fusion media and washed three times with fusion media. Cells were fixed with 3% paraformaldehyde and cluster number and length was counted using an Axion 200 inverted Zeiss fluorescence microscope. AChR clustering on rapsyn -/-myotubes was carried out by incubation overnight at 37°C with the optimal dilution of agrin in fusion media. Labelling of clusters was as described for C2C12 cells.
Analysis of colocalisation and clustering
16 bit-depth images from a radiance 2000 confocal microscope were analysed blinded using
MetaMorph, Universal Imaging Corporation. Colocalisation of rapsyn with AChR was quantitated as percent of green pixels colocalising with red pixels, and conversely colocalisation of AChR with rapsyn was quantitated as percent of red pixels colocalising with green pixels. Densitometry of rapsyn and AChR and area of clusters was also analysed using MetaMorph.
Results
Patients
Eighteen different mutations within or affecting the RAPSN coding region (Fig 1) were identified in patients with CMS associated with AChR deficiency. We chose five of these mutations, A25V, N88K, R91L, L361R, and K373del for functional studies to determine the underlying basis for the endplate AChR deficiency. These included four missense mutations and one single amino acid deletion within rapsyn. The patients with these mutations are described in Table 1 and include two pairs of siblings, patients 4 and 5, and 12 and 14. The age at onset varied from birth (ten patients) to later childhood (one patient) or adult life. In affected individuals each of these mutations was found to be heteroallelic with mutation N88K or homozygous for N88K.
Four of nine homozygous for N88K had arthrogryposis multiplex congenita (AMC) but congenital joint contractures were also evident in two other patients with compound heteroallelic mutations (not significant). Six of the patients with symptoms from birth had at least one exacerbation during childhood that required hospital admission, often with assisted ventilation during thee attacks. Apnoea attacks occurred in all three patients with the rapsyn mutation K373del, and in patient 6 (rapsyn mutations L361R and N88K) but only in 2/9 rapsyn patients homozygous for N88K (not significant). Patient 1 (rapsyn mutations A25V and N88K) and the siblings with rapsyn mutations K373del and N88K had older brothers with a similar phenotype to them, but who had died in infancy from respiratory failure.
All but patient 1 has been examined, usually on treatment, within the last two years. At his last (Table 1) which differ significantly between those homozygrous for N88K and those with compound heteroallelic mutations (Mann Whitney p=0.029).
Functional analysis of RAPSN mutations
To examine whether the clinical phenotype reflected the functional effects of the mutations on AChR clustering, cDNA encoding human rapsyn (Buckel et al., 1996) was cloned into mammalian expression vector pcDNA3.1 or given a C-terminal EGFP tag using pEGFP-N1. Preliminary experiments showed that inclusion of the C-terminal EGFP tag did not affect rapsyn-induced clustering of the AChR in the TE671 muscle cell line (data not shown). Subsequently respective mutations A25V, N88K, R91L, L361R
and K373del were introduced into the rapsyn-EGFP expression plasmid for the functional studies.
R91L inhibits rapsyn self-clustering
We first studied the effect of the mutations on rapsyn self-association, which is a critical process in the clustering of the AChR. To do this, plasmids constructed to express wild type or mutant rapsyn-EGFP were transfected into TE671 cells, images were captured on a confocal microscope ( Fig. 2A-F ) and the percent of fluorescent cells that contained clusters was counted. Western blots showed that the diffuse cellular EGFP signal was not due to protein degradation or GFP clipping (data not shown). R91L-rapsyn showed a significant reduction in self-association, with only 45% of fluorescent cells containing clusters compared with 75% for wild type (Fig 2G; repeated measures ANOVA, p=0.006, with post-test for rapsyn R91L, p<0.05). Even those cells that did contain clusters with R91L-rapsyn had very few large clusters per cell that were probably non-specific aggregates (Fig 2D) . By contrast, self-clustering in all the other rapsyn constructs was similar to the wild type. Since rapsyn self-association is crucial for AChR clustering, it is likely that this is the pathogenic mechanism for this mutation.
Mutation K373del reduces the stability of rapsyn
We next analysed the expression levels of the remaining four rapsyn mutants by western blotting.
Wild type or mutant rapsyn-EGFP was transfected on day 0 (with or without the AChR subunits) into TE671 cells, and a time course for levels of rapsyn and α-tubulin (control) was carried out. An example of TE671 cells transfected with rapsyn alone is shown in Fig 3A, and similar results were obtained when cells were cotransfected with AChR (data not shown). Densitometry was performed to obtain a ratio of rapsyn: α-tubulin and the results were normalized to levels of wild type-rapsyn-EGFP (Fig 3B) . K373del-rapsyn-EGFP expression drastically decreased to only approximately 10% that of wild type rapsyn by day 4 and was undetectable by day 5. This initial robust expression of K373del followed by rapid loss strongly suggests that deletion of K373 reduces the stability of rapsyn to a much greater extent than the other mutations. The same results were obtained with a second set of DNA preparations. A25V and L361R also reduced rapsyn levels to around 30% but interestingly N88K had no effect on rapsyn expression.
Immunocytometric analysis of the co-transfected TE671 cells confirmed the results from western blot analysis and also showed that cell surface expression of AChR was unaffected by the rapsyn mutations studied here (data not shown). The dramatic effect of K373del on rapsyn stability is likely to be the major molecular mechanism underlying rapsyn dysfunction for this mutation.
A25V-rapsyn does not associate with the AChR and abrogates AChR clustering
Next we investigated the effect of the remaining three mutations, A25V, N88K and L361R on the interactions between rapsyn and AChR by looking at colocalisation of the two proteins. First, in a blinded experiment, TE671 cells were co-transfected with wild type or mutant rapsyn-EGFP constructs and the AChR cDNAs. Two days following transfection the AChR was immunolabelled and the cells were fixed and mounted. Photographs were taken using a confocal microscope and colocalisation of rapsyn with AChR (% of green pixels that are also red) and AChR with rapsyn (% of red pixels that are also green) was analysed using MetaMorph. Figs 4A-D show examples of confocal images of the green fluorescent rapsyn constructs, AChR labelled with MAb B3 fluorescing red, and merged images. Wild type rapsyn-EGFP showed the best colocalisation with 62% colocalising with the AChR and 52% of AChR colocalising with rapsyn-EGFP ( Fig   4E) . A25V-Rapsyn-EGFP showed the least colocalisation, with only 10% of rapsyn colocalising with the AChR and 17% of AChR colocalising with rapsyn ( Fig 4E) . A25V-rapsyn did not localise at the cell surface; rather A25V-rapsyn-GFP clusters were bigger and appeared intracellularly, in the middle of the cell soma.
The AChR signal at the cell surface, in the A25V-rapsyn-EGFP/AChR co-transfections, showed minimal clustering ( Fig 4B) as would be expected in the absence of functional rapsyn. Rapsyn harbouring mutations N88K and L361R showed approximately a 50% reduction in levels of colocalisation of both rapsyn with AChR and AChR with rapsyn compared with wild type in TE671 cells (Fig 4E) ,
To further understand the effect of this rapsyn mutation on co-localisation we studied agrin-induced AChR clusters. Wild type-or A25V-rapsyn-EGFP were introduced into mouse rapsyn -/-myoblasts using retroviruses, myoblasts were fused and incubated with agrin overnight, and AChR clusters were visualised using α-BuTx-TRITC. Many clusters were induced as expected in myotubes expressing wild type-rapsyn-EGFP (Fig 5A) , but clusters in A25V-rapsyn-EGFP myotubes were virtually undetectable ( Fig 5B) whereas they were present with N88K and L361R (Fig 5C,D) . The number of clusters longer than 3μm was counted in each field. The A25V mutation reduced the number of clusters by 97.5% compared with that of wild typerapsyn-EGFP ( Fig 5E) . As expected, no clusters were observed in agrin-treated rapsyn -/-myotubes (data not shown).
Confocal images showed that the AChR was located along the cell surface of myotubes. In merged confocal images of agrin-treated myotubes expressing A25V-rapsyn-EGFP, the AChR appeared as red lines along the edge of the myotubes whereas A25V-rapsyn-EGFP was green inside the myotubes, indicating that rapsyn was not located at the cell surface and did not colocalise with the AChR (Fig5G) , confirming the results shown in TE671 cells (Fig. 4B) . By contrast, in merged images of myotubes expressing wild typerapsyn-EGFP, in addition to the presence of clusters, the edges of the myotubes were yellow indicating that rapsyn reached the cell surface and colocalised precisely with un-clustered AChR (Fig 5F) .
N88K-and L361R-rapsyn-EGFP form agrin-induced clusters that are unstable.
Despite the reduction in colocalisation of N88K-and L361R-rapsyn-EGFP with AChR in TE671 cells (Fig 4E) , they were still able to effectively mediate agrin-induced AChR clusters in rapsyn -/-myotubes ( Figs 5C and D) . However, the number of AChR clusters was reduced by 30% for N88K and by as much as 60% for L361R (Fig 5E) . The clusters that did form were similar to those formed by wild type-rapsyn-EGFP with respect to average area, density of rapsyn-EGFP, density of AChR and colocalisation of rapsyn with AChR (data not shown).
The reduction in number of clusters could be due to less efficient cluster formation or to clusters being unstable once formed. To test this myotubes were incubated overnight with agrin, washed three times to remove the agrin, and incubated in differentiation media for five hours prior to labelling with α-BuTx-TRITC (Fig 6A-F) . Over the five hour incubation period the number of AChR clusters per field with wild type-rapsyn-EGFP decreased by only 10% (Fig 6G) , indicating that the clusters are relatively stable. By contrast, with N88K-or L361R-rapsyn-EGFP the AChR clusters were disassembled as reflected by the 85% reduction in the number of clusters per field (Fig 6G) .
Discussion
We studied four missense mutations and one single amino acid deletion within rapsyn that are present in patients with congenital myasthenia due to endplate AChR deficiency. They were found to disrupt rapsyn function via different intracellular molecular mechanisms. R91L abrogates rapsyn self clustering, K373del leads to the rapid rapsyn degradation, and A25V annuls the association of rapsyn and AChR. The pathogenic mechanisms of N88K and L361R appear to be more subtle. Mutation L361R reduces the level of rapsyn either through lower expression or increased turnover. Both L361R and N88K affect the association of rapsyn with AChR, reduce the number of agrin-induced AChR clusters in rapsyn -/-myotubes and dramatically reduce the stability of AChR clusters. A summary of the results is shown in Table 2 .
Tetratricopeptide repeat domains mediate protein-protein interaction (Blatch and Lassle, 1999) . Rapsyn has a central region made up of multiple TPR domains, and deletion mapping identified TPR1 and TPR2 (domains as shown in Fig 1) as the most important for rapsyn self clustering. In addition deletion mutants of these domains were found to have a dominant negative effect on rapsyn self clustering when co-expressed with wild type rapsyn (Eckler et al., 2005) . R91L, located in TPR2, was the only one of the mutations we analysed that clearly affected rapsyn self association. This single missense substitution dramatically inhibited rapsyn-rapsyn oligomerisation, which, theoretically, should still be able to occur via any of the other six TPR domains. By contrast with the deletion experiments (Eckler et al 2005) , we did not obviously detect a dominant negative effect of R91L-rapsyn when co-expressed with wild type rapsyn-DsRed2 (data not shown), moreover in patients reviewed at the Oxford Myasthenia Clinic we have not identified a pedigree with rapsyn mutations in which there is a dominant inheritance pattern. However, the possibility of dominant rapsyn mutations should not be ruled out.
Deletion of lysine at position 373 reduces the levels of rapsyn in vitro. The mechanism for AChR deficiency could be due to the reduced levels of functional rapsyn in cells, or alternatively intrinsic rapsyn instability in vivo may lead to reduced stability of AChR clusters. In addition reporter gene assays indicate that mutations in the RAPSN promoter may cause congenital myasthenic syndromes through reduced expression of rapsyn mRNA , and consequently reduced rapsyn expression. The association of rapsyn with AChR leads to metabolic stabilisation of AChR in the postsynaptic membrane (Wang et al., 1999) and an increased ratio of rapsyn to AChR is thought to enhance AChR stability (Gervasio and Phillips, 2005; Losen et al., 2005) . It is not clear whether reduced rapsyn expression causes AChR deficiency through an effect on the clustering process itself or through instability of formed or partially formed clusters.
The A25V-rapsyn mutation has a profound effect on AChR clustering. In TE671 cells and rapsyn -/-myotubes, the mutant rapsyn was not present at the membrane and rarely colocalised with the AChR. When A25V-rapsyn-EGFP was expressed in rapsyn -/-myotubes agrin-induced clustering was almost completely abrogated. Another rapsyn mutation close to the N-terminus, L14P, previously reported (Ohno et al., 2002) gave a similar expression pattern (data not shown). A possible explanation for the action of these mutations is an effect on myristylation and thereby binding to the plasma membrane. Alternatively the rapsyn Nterminal region may be crucial for trafficking to the cell surface, or L14P and A25V may disrupt rapsynAChR interactions. However, previous reports have postulated that the coiled-coil domain (residues 298-331) is the major region responsible for these interactions (Bezakova and Bloch, 1998; Ramarao et al., 2001 ).
Studies of mutations N88K and L361R suggest they affect several aspects of rapsyn function. Both N88K-rapsyn and L361R-rapsyn showed similar functional characteristics in our expression systems, although lower levels of L361R-rapsyn were observed following transfection into TE671 cells due either to reduced L361R-rapsyn expression or stability. In TE671 cells both mutations led to an approximate 50% reduction in rapsyn colocalisation with AChR, and both formed reduced numbers of large aggregates of clusters. A decrease in colocalisation of N88K-rapsyn-EGFP and AChR in HEK 293 cells was previously observed (Ohno et al., 2002) . In agrin-induced AChR clusters in rapsyn -/-myotubes the number of clusters, compared to wild type, was decreased by approximately 30% (N88K) or 60% (L361L). However, when agrin was withdrawn, a dramatic decrease in the number of clusters compared with wild type was observed, indicating that clusters incorporating these two mutations are unstable.
A significant association with truncating mutations in the second allele and arthrogryposis has been noted (Beeson et al., 2005) suggesting that the lack of function of the second allele may influence disease se phenotype. Many factors, including age and the fluctuating course of the disorder make it very difficult to obtain an objective measure of disease severity. We applied the myasthenia gravis activities of daily living (MG-ADL) score to children as well as adults as a simple symptom-based questionnaire as a means of assessing disability when the patient is in a stable phase (Table 1 ). In our cases we found significantly higher MG-ADL scores in the patients with the functionally more disruptive mutations A25V, R91L and K373del (p = 0.024, Mann Whitney), even when including N88K homozygous patients 11 and 12 where MG-ADL scores were likely to be increased by co-morbid conditions (patient 11 also has Perthe's disease and both patients 11 and 12 had a body mass index of approximately 40).
Other anecdotal evidence suggesting an involvement of the second mutation with disease severity is that we have not identified deaths in siblings in kinships where the affected child is homozygous for N88K;
none of the patients homozygous for N88K have required 3,4-diaminopyridine in addition to their anticholinesterase treatment, implying either that their disease may be less severe or that they respond better to anticholinesterase medication; and 4 out 5 of our late onset cases of AChR deficiency due to rapsyn mutations are homozygous for N88K.
We dissected the pathogenic mechanisms of five naturally occurring rapsyn mutations. The data supports the hypothesis that dysfunction in the second mutation of a heteroallelic N88K-rapsyn patient contributes to disease severity. It is tempting to speculate that the underlying cause of the fever-induced severe apnoeic attacks associated with rapsyn mutations is increased N88K-rapsyn-AChR-cluster instability.
A raised body temperature might lead to an increase in both protein metabolism and membrane fluidity, thus compromising the structural integrity of the already unstable AChR clusters. Moreover, the similarity in functional characteristics of N88K-rapsyn and L361-rapsyn revealed in this study suggests that there are likely to be patients with AChR deficiency that are either homozygous or heteroallelic for non-N88K mutations within the RAPSN coding region. that it is unstable. A25V and L361R were also unstable but to a lesser degree, and N88K-rapsyn-EGFP was as stable as wild type rapsyn. Magnification 60x. Bar = 10μm. E. MetaMorph was used to calculate colocalisation of rapsyn with AChR (% green pixels that are red) and AChR with rapsyn (% red pixels that are green). 
